Target Name: ANO10
NCBI ID: G55129
Other Name(s): Anoctamin-10 | MGC47890 | ANO10_HUMAN | Anoctamin-10 (isoform 3) | Anoctamin 10, transcript variant 9 | Anoctamin-10 (isoform 5) | ANO10 variant 1 | Anoctamin-10 isoform X1 | OTTHUMP00000209959 | OTTHUMP00000209958 | TMEM16K | Anoctamin 10, transcript variant 2 | Anoctamin-10 (isoform 1) | Anoctamin-10, transcript variant X1 | SCAR10 | anoctamin 10 | ANO10 variant X1 | Anoctamin 10, transcript variant 5 | OTTHUMP00000164038 | OTTHUMP00000164039 | Anoctamin-10 (TMEM16K) | Anoctamin-10 (isoform 2) | ANO10 variant 9 | transmembrane protein 16K | Transmembrane protein 16K | FLJ10375 | ANO10 variant 2 | Anoctamin 10, transcript variant 1 | ANO10 variant 5 | OTTHUMP00000209960

ANOCTAMIN-10: A drug target and biomarker for the treatment of chronic pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The chronicity of pain makes it difficult for patients to lead a normal life and can lead to significant physical and mental morbidities. The most common causes of chronic pain are musculoskeletal, neuropathic, and rheumatic disorders. These conditions can be debilitating and often limit a person's quality of life. The lack of effective treatments for chronic pain has led to a significant burden on healthcare systems and the economy.

Annoctamin-10 (ANOCTAMIN-10) is a drug target and biomarker that has the potential to treat chronic pain. It is a small molecule that can inhibit the activity of pain-sensitive neurons. ANOCTAMIN-10 is derived from the natural compound annotation (ANNO) and its structure is similar to that of other annelated compounds, such as bromodomain and extraterminal domain (BED) proteins.

ANOCTAMIN-10's unique feature is its ability to selectively inhibit pain-sensitive neurons, without affecting other types of neurons. This means that it can be used to treat chronic pain without causing unintended side effects. Additionally, ANOCTAMIN-10 is a non-steroidal anti-inflammatory drug (NSAID), which means that it has a lower risk of stomach ulcers compared to other classes of pain medications.

The search for new treatments for chronic pain has led to the development of ANOCTAMIN-10 as a potential drug target. ANOCTAMIN-10 has been shown to reduce pain in animal models of chronic pain, including pain caused by muscle-related conditions, neuropathic pain, and rheumatoid arthritis.

ANOCTAMIN-10's ability to selectively inhibit pain-sensitive neurons has led to its potential as a treatment for chronic pain. By blocking the activity of pain-sensitive neurons, ANOCTAMIN-10 can effectively reduce pain. Additionally, ANOCTAMIN-10's lack of unintended side effects makes it a potential candidate for long-term pain management.

The development of ANOCTAMIN-10 as a drug target for chronic pain is an exciting new development in the field of pain management. ANOCTAMIN-10's ability to selectively inhibit pain-sensitive neurons and its non-steroidal anti-inflammatory properties make it a promising candidate for the treatment of chronic pain.

Conclusion

Chronic pain is a significant public health issue that can have a significant impact on a person's quality of life. The lack of effective treatments for chronic pain has led to a significant burden on healthcare systems and the economy. ANNOCTAMIN-10 is a drug target and biomarker that has the potential to treat chronic pain. Its unique feature is its ability to selectively inhibit pain-sensitive neurons without affecting other types of neurons. Additionally, ANOCTAMIN-10 is a non-steroidal anti-inflammatory drug, which means that it has a lower risk of stomach ulcers. The development of ANOCTAMIN-10 as a potential drug target for chronic pain is an exciting new development in the field of pain management. Further research is needed to determine its effectiveness and safety in the treatment of chronic pain.

Protein Name: Anoctamin 10

Functions: Does not exhibit calcium-activated chloride channel (CaCC) activity. Can inhibit the activity of ANO1

More Common Targets

ANO2 | ANO3 | ANO4 | ANO5 | ANO6 | ANO7 | ANO7L1 | ANO8 | ANO9 | Anoctamin | ANOS1 | ANOS2P | ANP32A | ANP32A-IT1 | ANP32AP1 | ANP32B | ANP32C | ANP32D | ANP32E | ANPEP | ANTKMT | ANTXR1 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA10 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA2R | ANXA2R-AS1 | ANXA2R-OT1 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | ANXA8 | ANXA8L1 | ANXA8L2 | ANXA9 | AOAH | AOC1 | AOC2 | AOC3 | AOC4P | AOPEP | AOX1 | AOX2P | AP-1 Transcription Factor Complex | AP1AR | AP1B1 | AP1B1P1 | AP1G1 | AP1G2 | AP1M1 | AP1M2 | AP1S1 | AP1S2 | AP1S3 | AP2A1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3B1 | AP3B2 | AP3D1 | AP3M1 | AP3M2 | AP3S1 | AP3S2 | AP4B1 | AP4B1-AS1 | AP4E1 | AP4M1 | AP4S1 | AP5B1 | AP5M1 | AP5S1 | AP5Z1 | APAF1 | APBA1 | APBA2 | APBA3 | APBB1 | APBB1IP | APBB2 | APBB3 | APC | APC2 | APCDD1 | APCDD1L | APCDD1L-DT | APCS | APEH